Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib rollover study for continued treatment access in myelofibrosis
2023-507225-42-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ruxolitinib in myelofibrosis (MF) (3 arms), sponsored by Incyte. Primary endpoint: Safety (adverse events and serious adverse events). Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2023-507225-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507225-42-00.